Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 Apr 12.
Published in final edited form as: Tetrahedron. 2019 Feb 26;75(15):2261–2264. doi: 10.1016/j.tet.2019.02.054

Synthesis of 2-D-L-Tryptophan by Sequential Ir-Catalyzed Reactions

Ravikrishna Vallakati 1, Abel T Plotnikov 1, Ryan A Altman 1
PMCID: PMC6532784  NIHMSID: NIHMS1522853  PMID: 31130755

Abstract

Herein, we report a practical synthesis of 2-D-L-tryptophan via sequential Ir-catalyzed C–H borylation, and Ir-catalyzed C-2-deborylative deuteration steps. In this synthetic sequence, deprotection of the Boc and methyl ester groups proved challenging, due to replacement of deuterium with hydrogen. However, mild deprotection conditions were developed to avoid this D/H scrambling. Further, 2-D-L-Tryptophan is stable in many buffers used for biological studies.

Keywords: L-Tryptophan, C–H Borylation, Deborylative deuteration, Metal-Catalysis, Deuterium labeling

Graphical Abstract

graphic file with name nihms-1522853-f0005.jpg

1. Introduction:

Deuterated compounds possess many uses in synthetic organic, biological and medicinal chemistries. In synthetic chemistry, deuterated compounds are used (i) to study reaction mechanisms through experimentally observed kinetic isotopic effects,1 and by deuterium labeling experiments,2 (ii) as analytical standards in quantitative analysis of C-deuterated drugs,3 (iii) to alter chemoselectivity and regioselectivity in the synthesis of natural products,4 and (iv) to aid in the structural elucidation of peptides.5 In biological systems, deuterium can enhance absorption, distribution, metabolism and excretion properties (ADME) of bioactive molecules,6,7 which can lower the doses and subsequent toxicity of drugs.8 In fact, a deuterium-containing drug, deutetetrabenazine, was approved recently to treat chorea associated with Huntington’s disease.9 Deudextromethorphan (AVP-786), another deuterium-containing drug candidate, is currently in phase II and III clinical trials for the treatment of residual schizophrenia, intermittent explosive disorder, neurobehavioral disinhibition in patients with traumatic brain injury, and agitation in patients with Alzheimer’s dementia.10,11

Various deuterated tryptophan (Trp) analogs have been used to study: (i) protein structure by neutron scattering,12 (ii) amino acid metabolism,13 and (iii) enzymatic mechanisms.14 Though these studies have been predominantly conducted with perdeuterated5 probes containing or deuterium at C4 and C5 positions,14 C-2-deuterated L-Trp might provide more insights into the biosynthesis of Trp-derived natural products, particularly in steps that involve indole C2–C3 bond cleavage.15 However, no strategy exists to selectively generate 2-D-Trp. Traditional methods to incorporate deuterium on aromatic and heteroaromatic compounds, such as hydrogen-deuterium exchange and metal-halogen exchange followed by deuteration, are not suitable for selective C-2 deuteration of Trp, as those methods suffer from poor selectivity, harsh reaction conditions, and poor functional group tolerance.16 A minor amount of deuteration at C-2 (7%) was observed of Trp in an attempt to regioselectively deuterate the C-4 position using photochemical conditions; though optimization of this side reaction was not pursued.17 A possible synthesis of Trp-derivatives with 2-D substitution on the indole ring might involve electrophilic substitution at the C-3 carbon of C-2-deuterated indole with L-Serine followed by enzymatic resolution.18 However, this strategy suffers complete erosion of enantioselectivity in the first step and requires prior deuteration of the indole.19 In contrast, we envisioned that a more practical approach might involve late-stage deuteration of a C-2-metallated Trp derivative.20 Herein, we describe the selective synthesis of 2-D-L-Trp starting from L-Trp, using sequential Ir-catalyzed reactions and SiO2-assisted global deprotection.

2. Results and Discussion:

We envisioned that protected Trp (1) could convert to the C2-deuterated analog via sequences involving either (i) bromination and subsequent Pd-catalyzed debromodeuteration,21 or (ii) C2-selective Ir-catalyzed C–H borylation, then Ir-catalyzed deborylative deuteration. Though both 2-Br-Trp and 2-Bpin-Trp are known, the subsequent C–D bond forming reactions have not been tested on Trp derivatives. Finally, acid-mediated global deprotection would furnish the target compound (Scheme 1), though acid-catalyzed D/H scrambling of the C-2 position would ultimately complicate this reaction.

Scheme 1:

Scheme 1:

Synthetic Plan to Synthesize 2-D-L-Trp (5)

Synthetic work commenced by esterification of L-Trp (6)22 followed by N-acetylation.23 Initial attempts to brominate N-acetyl-L-tryptophan methyl ester at 2-position provided low yield of desired product. In contrast, use of a trifluoroacetyl protecting group enabled bromination in modest yield.24 However, Pd-catalyzed debromodeuteration did not provide deuterated tryptophan (9) using previously reported conditions (Scheme 2).21,25

Scheme 2:

Scheme 2:

Attempted Preparation of Protected 2-D-L-Trp Analog by Pd-Catalyzed Debromodeuteration

After exploring the Pd-catalyzed route, we focused on a second strategy involving sequential Ir-catalyzed borylation of arenes2629 and deborylative deuteration.28b N-Boc-L-Trp methyl ester (10) was subjected to Ir-catalyzed microwave-assisted borylation conditions with B2Pin2 to provide 2-Bpin-Trp derivative (11) as the major product, along with a small quantity of the 2,7-diborylated product, which was separated by column chromatography. The 2-Bpin-Trp derivative (11) was then treated with [Ir(OMe)(cod)]2 in THF/D2O (6:1) to provide 2-D-L-Trp methyl ester (12, Scheme 3) in 90% purity, with nondeuterated N-Boc-Trp-OMe (10) remaining as an inseparable impurity.

Scheme 3:

Scheme 3:

Preparation of 2-D-L-Trp Methyl Ester (12) Using Ir-Catalyzed C–H Borylation and Deuteration Reactions

Subsequent deprotection proved challenging due to an unexpected C–D to C–H scrambling event under acidic conditions. Specifically, removal of the Boc group with aqueous HCl facilitated D replacement with H to produce L-Trp methyl ester (13).27 Similar D/H scrambling occurred, using TFA in dichloromethane in the presence of tertiary butyl cation scavengers (dimethyl sulfide and 1,2-ethane dithiol), though these conditions did not remove the Boc group.28 However, treatment of compound 12 with SiO2 in D2O29 at 140 °C for 10 h not only suppressed D/H scrambling, but also both removed the Boc group and hydrolyzed the methyl ester to provide the target compound 2-D-L-Trp (5) in excellent yield (Scheme 4).

Scheme 4:

Scheme 4:

Deprotection of N-Boc-2-D-L-Trp Methyl Ester (12)

Despite the instability towards strong acids, compound 5 is stable to many buffers relevant for biological studies. To establish the stability of the compound 2-D-L-Trp (5) in acidic, basic and buffer solutions, we treated the 90% pure compound with 1.0 N HCl, 1.0 N NaOH and with various buffers that are generally used in biological studies. By 1H NMR of the crude reaction mixtures, scrambling occurred in 1.0 N HCl. However, no D/H scrambling occurred in 0.1 N Na2HPO4, 1.0 N NaOH, TBS, PBS, HEPES buffers (Table 1). As such, 2-D-L-Trp (5) should serve use in biological studies.

Table 1:

Stability Data for 2-D-L-Trp (5)

graphic file with name nihms-1522853-t0006.jpg

Entry# Reagent %Da
1 1.0 N HCl 72%
2 0.1 M Na2HPO4 (pH 7.4) 89%
3 1.0 N NaOH 90%
4 bTBS Buffer 90%
5 cPBS Buffer 90%
6 dHEPES Buffer 90%
7 eTris Buffer 90%
a

by 1HNMR of the crude reaction mixture.

b

50 mM Tris, 150 mM NaCl

c

8 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 13.7 mM NaCl

d

50 mM HEPES, 150 mM NaCl

e

50 mM Tris-HCl, 200 mM NaCl, 5% Glycerol

3. Conclusion:

In conclusion, we prepared 2-D-L-Trp (5) using a selective C–H activation and functionalization strategy via Ir-catalyzed borylation and selective deborylative deuteration. To overcome D scrambling during acidic deprotection and work up, we identified neutral conditions for deprotection that retained D at the C2 position. This deuterated probe is stable in several media used for biological studies and should serve many uses in chemical biology.

4. Experimental Section:

Section A: General Considerations

Unless otherwise noted, all reactions were performed using oven-dried glassware under an atmosphere of dry N2. Ir-catalyzed deborylative deuteration reaction was performed in a resealable 15 mL screw-top vial sealed with a PTFE septum. All other reactions were performed in round-bottom flasks sealed with rubber septa. Stainless steel syringes were used to transfer air- or moisture-sensitive liquid reagents. Reactions were monitored by thin-layer chromatography (TLC) on UNIPLATE™ Silica Gel HLF 250-micron glass plates precoated with 230–400 mesh silica impregnated with a fluorescent indicator (250 nm) and visualized by UV irradiation (254 nm). A CombiFlash® RF–4× purification system was used for chromatographic purifications. Silica gel was purchased from Sorbent Technologies (cat. #30930M-25, 60 Å, 40–63 μm). Unless otherwise noted, reagents were purchased from commercial sources and used as received. Anhydrous acetonitrile (CH3CN), methanol (MeOH), dichloromethane (DCM), tetrahydrofuran (THF), toluene, and triethylamine (NEt3) were dispensed from a solvent purification system, in which the solvent was dried by passage through two columns of activated alumina under argon.

Melting points were measured using a Thomas-Hoover melting point apparatus. Proton nuclear magnetic resonance (1H NMR) spectra, and carbon nuclear magnetic resonance (13C NMR) spectra were recorded on a Bruker 500 AVANCE spectrometer (500 and 126 MHz, respectively) or a Bruker 400 AVANCE spectrometer (400 and 101 MHz, respectively). Chemical shifts (δ) for protons are reported in parts per million (ppm) and are respectively referenced to the proton resonance of residual MeOH or H2O in the NMR solvent (δ = 3.31 ppm, and 4.87) and for D2O (δ = 4.79 ppm). Chemical shifts (δ) for carbon are reported in ppm and are referenced to the carbon resonances of the CDCl3 solvent peak (δ = 77.16 ppm). NMR data are represented as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = multiplet), coupling constant in Hertz (Hz), and integration. Exact mass determination was obtained by the following method: electron impact ionization (EI) on a ZG analytical ZAB mass spectrometer or electrospray ionization (ESI) on a SI-3 Waters LCT Premier™ mass spectrometer.

Section B: Experimental Procedures

Compounds 7, 8,22,24 10, and 1129 were prepared based on the literature procedure.

Methyl (tert-butoxycarbonyl)-L-tryptophanate-2-D (12)

To a 20 mL microwave vial were added 2-BPin-WBoc-N-tryptophan methyl ester (11) (0.60 g, 1.35 mmol, 1 equiv) and [Ir(cod)(OMe)]2 (18.0 mg, 0.027 mmol, 2 mol%). The vial was sealed, evacuated and backfilled with N2 three times. Dry THF (6.0 mL) was added, followed by D2O (1.0 mL). The reaction mixture was stirred at 80 °C for 2.5 h. Before unsealing the vial, the pressure was released by slowly inserting an open needle. Water (10.0 mL) was added to the reaction mixture and the aqueous layer was extracted with EtOAc (3 × 20.0 mL). The combined organic layer was then washed with brine (20.0 mL), dried over MgSO4, filtered, and adsorbed onto 2.0 g silica gel. Purification by silica gel chromatography (EtOAc/hexanes: 0% to 40%) yielded a tan solid (352.0 mg, 82% yield with 90% compound 12 and 10% nondeuterated N-Boc-Trp-OMe (10) impurity). m.p.: 145–146 °C. 1H NMR (400 MHz, MeOD) δ 7.53 (d, J = 8.0 Hz, 1 H), 7.34 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1 H), 7.03 (t, J = 8.0 Hz, 1 H), 4.44 (t, J = 8.0 Hz, 1H), 3.65 (s, 3H), 3.27 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 3.14 (dd, J = 8.0 Hz, 8.0 Hz, 1H), 1.39 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.8, 155.2, 136.0, 127.6, 122.2, 119.6, 118.7, 111.2, 110.0, 79.9, 54.1, 52.3, 28.3, 27.9. 2H NMR (126 MHz, MeOH) δ 7.06. HRMS (ESI) calculated for C17H21DN2O4K [M+K]+ m/z 358.1279, found m/z 358.1295, 4.5 ppm.

(S)-2-Ammonio-3-(1H-indol-3-yl-2-d)propanoate (5)

To a solution of Methyl (tert-butoxycarbonyl)-L-tryptophanate-2-D (12) (10.0 mg, 0.031 mmol, 1.0 equiv) in DCM (1.0 mL) was added silica gel (66.0 mg, 60 Å). The solvent was removed under reduced pressure to adsorb compound onto silica gel. In a 5 mL round bottom flask equipped with a water condenser, the adsorbed material was suspended in 1.0 mL D2O and heated to 140 °C for 10 h. The reaction mixture was cooled to room temperature, then filtered by Buckner funnel under vacuum and washed with H2O (1.0 mL) and DCM (3 × 2.0 mL) to remove the silica gel. The filtrate was diluted with H2O (3.0 mL) to separate layers. The aqueous layer was further extracted with DCM (2 × 3.0 mL) to remove any organic impurities present in the solution. The aqueous layer was then dried under vacuum to provide the desired compound 5 as a white solid (5.7 mg, 90%). m.p.: 245–246 °C. 1H NMR (400 MHz, D2O) δ 7.71 (d, J = 8.0 Hz, 1 H), 7.51 (d, J = 8.0 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 7.19 (t, J = 8.0 Hz, 1H), 4.02 (dd, J = 8.0, 4.0 Hz, 1H), 3.47 (dd, J = 16.0, 8.0 Hz, 1H), 3.23 (dd, J = 16.0, 8.0 Hz, 1H). 13C NMR (126 MHz, D2O) δ 174.7, 136.25, 126.6, 124.9, 122.0, 119.4, 118.4, 111.9, 107.3, 55.0, 26.4, 7.1. 2H NMR (126 MHz, MeOH) δ 7.18. HRMS (ESI) mass calculated for C11H11DN2O2 [M-H]+ m/z 204.0883, found m/z 204.0891, 3.9 ppm.

Procedure for 2-D-L-Trp (5) Stability Test

In a 1-dram vial, 2-D-L-Trp (5, 0.05 M) was added to the reagent (1.0 N HCl, 0.1 M Na2HPO4, 1.0 N NaOH, TBS buffer, PBS buffer, HEPES buffer) and stirred for 24 h at room temperature. The solvent was removed in vacuo to obtain crude material as solid. The material was re-dissolved into D2O to obtain a 1H NMR spectrum.

Supplementary Material

1

6. Acknowledgements:

Financial support by NIGMS (R35 GM124661) is gratefully acknowledged. Support for the NMR instrumentation was provided by NIH Shared Instrumentation Grant (S10OD016360) and NIH Shared Instrumentation Grant (S10RR024664) and NSF Major Research Instrumentation Award (1625923). Support for the Mass Spectrometry was provided from NIH (SIG S10 RR019398).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

5. Supplementary data:

1H NMR, 13C NMR and 2H NMR for new compounds 12 and 5 and can be found at https://doi.org/10.1016/j.tet.2019.02.054.

7. References:

  • 1.Gant TG J. Med. Chem. 2014, 57, 3595–3611. [DOI] [PubMed] [Google Scholar]
  • 2.Matsuda T; Shigeno M; Murakami M J. Am. Chem. Soc. 2007, 129, 12086–12087. [DOI] [PubMed] [Google Scholar]
  • 3.Bergner G; Albert CR; Schiller M; Bringmann G; Schirmeister T; Dietzek B; Niebling S; Schlücker S; Popp J Analyst 2011, 136, 3686–3693. [DOI] [PubMed] [Google Scholar]
  • 4.(a) Miyashita M; Sasaki M; Hattori I; Sakai M; Tanino K. Science 2004, 305, 495–499. [DOI] [PubMed] [Google Scholar]; (b) Quasdorf KW; Huters AD; Lodewyk MW; Tantillo DJ; Garg NK J. Am. Chem. Soc. 2012, 134, 1396–1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Blomquist AT; Cedergren RJ; Hiscock BF; Tripp SL; Harp DN Proc. Natl. Acad. Sci. 1966, 55(3), 453–456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schofield J; Brasseur D; Bruin B; Vassal T; Klieber S; Arabeyre C; Bourrie M; Sadoun F; Fabre G J. Labelled Compd. Radiopharm. 2013, 56, 504–512. [DOI] [PubMed] [Google Scholar]
  • 7.Sharma R; Strelevitz TJ; Gao H; Clark AJ; Schildknegt K; Obach RS; Ripp SL; Spracklin DK; Tremaine LM; Vaz ADN Drug Metab. Dispos. 2012, 40, 625–634. [DOI] [PubMed] [Google Scholar]
  • 8.Morgan AJ; Nguyen S; Uttamsingh V; Bridson G; Harbeson S; Tung R; Masse CE J. Labelled Compd. Radiopharm. 2011, 54, 613–624. [Google Scholar]
  • 9.Dean M; Sung VW Drug. Des. Develop. Ther. 2018, 2, 313–319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Garay RP; Grossberg GT. Expert Opin. Investig. Drugs. 2017, 26, 121–132. [DOI] [PubMed] [Google Scholar]
  • 11.a) ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. February 29- Identifier NCT02477670, Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia; 2015 June 23 [cited 2018 Aug 1]; [1 screen]. Available from: https://clinicaltrials.gov/ct2/show/NCT02477670?cond=AVP-786&rank=2; b) ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. February 29- Identifier NCT01787747, Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers; 2013 Feb 11 [cited 2014 Jun 26]; [1 screen]. Available from: https://clinicaltrials.gov/ct2/show/NCT01787747?cond=AVP-786&draw=3&rank=7; c) ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. February 29- Identifier NCT03420222, Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder; 2018 Feb 02 [cited 2018 May 24]; [1 screen]. Available from: https://clinicaltrials.gov/ct2/show/NCT03420222?cond=AVP-786&rank=1
  • 12.Laux V; Callow P; Svergun DI; Timmins PA; Forsyth VT; Haertlein M Eur. Biophys. J. 2008, 37, 815–822. [DOI] [PubMed] [Google Scholar]
  • 13.Rittenberg D; Keston AS; Schoenheimer R; Foster GL J. Biol. Chem, 1938, 125, 1–12. [Google Scholar]
  • 14.Winnicka E; Kanska M J. Radioanal. Nucl. Chem. 2009, 279, 675–678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alkhalaf LM; Ryan KS Chem. Biol. 2015, 22, 317–328. [DOI] [PubMed] [Google Scholar]
  • 16.a) Atzrodt J; Derdau V; Fey T; Zimmermann J Angew. Chem., Int. Ed. 2007, 46, 7744–7765. [DOI] [PubMed] [Google Scholar]; b) Alonso F; Beletskaya IP; Yus M. Chem. Rev. 2002, 102, 4009–4091. [DOI] [PubMed] [Google Scholar]
  • 17.(a) Saito I; Sugiyama H; Yamamoto A; Muramatsu S; Matsuura T. J. Am. Chem. Soc. 1984, 106, 4286–4287. [Google Scholar]; (b) Saito I; Muramatsu S; Sugiyama H; Yamamoto A; Matsuura T Tetrahedron Lett. 1985, 26, 5891–5894. [Google Scholar]
  • 18.Blaser G; Sanderson JM; Batsanov AS; Howard J. A.k. Tetrahedron Lett. 2008, 49, 2795–2798. [Google Scholar]
  • 19.Wang X; Zhu M-H; Schuman DP; Zhong D; Wang W-Y; Wu L-Y; Liu W; Stoltz BM; Liu W-B. J. Am. Chem. Soc. 2018, 140, 10970–10974. [DOI] [PubMed] [Google Scholar]
  • 20.Grainger R; Nikmal A; Cornella J; Larrosa I Org. Biomol. Chem. 2012, 10, 3172–3174. [DOI] [PubMed] [Google Scholar]
  • 21.Donald CS; Moss TA; Noonan GM; Roberts B; Durham EC Tetrahedron Lett. 2014, 55, 3305–3307. [Google Scholar]
  • 22.Williams TJ; Reay AJ; Whitwood AC; Fairlamb IJS. Chem. Commun. 2014, 50, 3052–3054. [DOI] [PubMed] [Google Scholar]
  • 23.Reay AJ; Williams TJ; Fairlamb IJS. Org. Biomol. Chem. 2015, 13, 8298–8309. [DOI] [PubMed] [Google Scholar]
  • 24.Phillips RS; Cohen LA J. Am. Chem. Soc. 1986, 108, 2023–2030. [Google Scholar]
  • 25.a) Janni M; Perunchralathan S. Org. Biomol. Chem. 2016, 14, 3091–3091. [DOI] [PubMed] [Google Scholar]; b) Kuriyama M; Hamaguchi N; Yano G; Tsukuda K; Sato K; Onomura O. J. Org. Chem. 2016, 81, 8934–8946. [DOI] [PubMed] [Google Scholar]
  • 26.(a) Ishiyama T; Takagi J; Ishida K; Miyaura N; Anastasi NR; Hartwig JF. J. Am. Chem. Soc. 2002, 124, 390–391. [DOI] [PubMed] [Google Scholar]; (b) Takagi J; Sato K; Hartwig JF; Ishiyama T; Miyaura N Tetrahedron Lett. 2002, 5649–5651. [Google Scholar]; (c) Ishiyama T; Nobuta Y; Hartwig JF; Miyaura N Chem. Commun. 2003, 2924–2925. [DOI] [PubMed] [Google Scholar]; (d) Ishiyama T; Takagi J; Yonekawa Y; Hartwig JF; Miyaura N Adv. Synth. Catal. 2003, 345, 1103–1106. [Google Scholar]
  • 27.(a) Tse MK; Cho J-Y; Smith MR. Org. Lett. 2001, 3, 2831–2833. [DOI] [PubMed] [Google Scholar]; (b) Chotana GA; Rak MA; Smith MR J. Am. Chem. Soc. 2005, 127, 10539–10544. [DOI] [PubMed] [Google Scholar]; (c) Paul S; Chotana GA; Holmes D; Reichle RC; Maleczka RE Jr.; Smith MR III. J. Am. Chem. Soc. 2006, 128, 15552–15553. [DOI] [PubMed] [Google Scholar]
  • 28.(a) Kallepalli VA; Shi F; Sulagna P; Onyeozili EN; Maleczka RE; Smith MR. J. Org. Chem. 2009, 74, 9199–9201. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Kallepalli VA; Gore KA; Shi F; Snachez L; Chotana GA; Miller SL; Maleczka RE; Smith MR J. Org. Chem. 2015, 80, 8341–8353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Meyer FM; Liras S; Guzman-Perez A; Perreault C; Bian J; James K Org. Lett. 2010, 12, 3870–3873. [DOI] [PubMed] [Google Scholar]
  • 30.Zlatopolskiy BD; Zischler J; Schaefer D; Urusova EA; Guliyev M; Bannykh O; Endepols H; Neumaier B J. Med. Chem. 2018, 61, 189–206. [DOI] [PubMed] [Google Scholar]
  • 31.Chiotellis A; Mu L; Muller A; Selivanova SV; Keller C; Schibli R; Kramer SD; Ametamey SM Eur. J. Med. Chem. 2013, 70, 768–780. [DOI] [PubMed] [Google Scholar]
  • 32.Hudlicky T; Rinner U; Finn KF; Ghiviriga I J. Org. Chem. 2005, 70, 3490–3499. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES